Heparinoid

Heparinoids are glycosaminoglycans which are derivatives of heparin.[1] They include oligosaccharides and sulfated polysaccharides of plant, animal, or synthetic origin.[2] (More than) one study[3] has been conducted on heparinoids.[4]

Heparinoids, like heparin, act by interacting with heparin binding proteins, generally through ionic interactions or hydrogen bonding. Some examples of heparin binding proteins include antithrombin III. It is thought that much protein interaction with heparin is not direct, and instead heparin binding protein actually interact with glycosaminoglycan (GAG) side chains or mucins bound to the heparin polymer, so it is possible that heparinoids interact with these proteins in a similar way, acquiring GAG side chains in vivo. One counter example is the protein chymase, which directly binds to heparin.[2]

Sulfated polysaccharides

From animal tissues

Dermatan sulfate is one example of a compound that is classified as a heparinoid. It is a naturally-occurring polysaccharide of O-sulfated N-acetyl-D-galatosamine, L-iduronic acid, and D-glucuronic acid that has been clinically used as an antithrombotic agent.[2]

Chondroitin sulfate shows slightly less biological activity than dermatan sulfate, and is composed of O-sulfated N-acetyl-D-galatosamine and D-glucuronic acid. It is theorized that this change in efficacy is related to the absence of L-induronic acid, which affects the flexibility of the polymer chain.[2]

Acharan sulfate is a heparinoid that is naturally produced by the giant African land snail, Achatina fulica. Keratan sulfate is a heparinoid that is a component of cartilage. It is found in the cornea.[2]

Chitin, a component of insect shells and fungal structures, can be de-N-acetylated to form chitosan, which when sulfated has a significant chemical similarity to heparin. In fact, it inhibits thrombin by affecting ATIII.

Lepirudin is a recombinant preparation of the polypeptide anticoagulant secreted by leeches and is used in patients with heparin induced thrombocytopenia.

From plant sources

Fucoidan is a polymer composed of sulfated L-fucose.

Carrageenans are isolated from algae.

Hyaluronan functions as a heparinoid when it is sulfated. Intra-articular injections of hyaluronic acid are used to mitigate pain and treat symptoms of osteoarthritis in the knee, but such injections are correlated with increased risk of serious side effects.[5]

Alginic acid functions as a heparinoid when it is sulfated.

Pentosan from the bark of Fagus sylvatica, when sulfated, acts with 1/10th of the efficacy of heparin.

From microbial sources

K5 polysaccharide from E. coli acts as a heparinoid when it is sulfated.

History

Heparin was first isolated from dog liver by medical student Jay McClean in 1916. Jorpes discovered the structure of the heparin polysaccharide in 1935, identifying that it is a highly sulfated polymer of glycosaminoglycoglycan (GAG) and uronic acid. Around that time, heparin began to be used in the prophylaxis and treatment of post-operative thrombosis.[6]

Production

There is no industrial process for the complete synthesis of heparin; Heparin is isolated from animal tissue - generally bovine lung, porcine, and intestinal mucosa.[6] Heparinoids generally are also naturally-occurring polysaccharides, and similarly need to be purified from the plant or animal tissue that produces them.

Regulation

There is no internationally accepted molecular standard for the composition of heparin, as it is a complex polymer of GAG units and uronic acids (including D-glucuronic acid, L-iduronic acid, and D-glucosamine). Position of N-acetyl, N-sulfate, and O-sulfate groups in these uronic acids can vary, as can the branching patterns of the chain. This generates an extraordinary amount of variability between molecules of heparin.[6] Current USP standards for heparin limit levels of contamination with dermatan, chondroitin, and over-sulfated chondroitin sulfate, as well as galactosamine levels in the sample, as determined by HPLC, H-NMR, and Strong Anion Exchange Chromatography.[7][8]

See also

References

  1. ↑ Heparinoids at the US National Library of Medicine Medical Subject Headings (MeSH)
  2. 1 2 3 4 5 Gunay NS, Linhardt RJ (1999). "Heparinoids: structure, biological activities and therapeutic applications". Planta Medica. 65 (4): 301–6. doi:10.1055/s-1999-13990. PMID 10364832.
  3. ↑ Vecchio, Cesare; Frisinghelli, Anna (2008). "Topically Applied Heparins for the Treatment of Vascular Disorders: A Comprehensive Review". Clinical Drug Investigation. 28 (10): 603–614. doi:10.2165/00044011-200828100-00001. PMID 18783299. S2CID 31783368.
  4. ↑ Mehta PP, Sagar S, Kakkar VV (1975). "Treatment of superficial thrombophlebitis: a randomized, bouble-blind trial of heparinoid cream". British Medical Journal. 3 (5984): 614–6. doi:10.1136/bmj.3.5984.614. JSTOR 20406780. PMC 1674425. PMID 51664.
  5. ↑ Rutjes, Anne W.S.; Jüni, Peter; Da Costa, Bruno R.; Trelle, Sven; Nüesch, Eveline; Reichenbach, Stephan (2012). "Viscosupplementation for Osteoarthritis of the Knee". Annals of Internal Medicine. 157 (3): 180–91. doi:10.7326/0003-4819-157-3-201208070-00473. PMID 22868835. S2CID 5660398.
  6. 1 2 3 Linhardt, Robert J.; Toida, Toshihiko (1997). "Heparin oligosaccharides: New analogues development and applications" (PDF). In Witczak, Zbigniew J.; Nieforth, Karl A. (eds.). Carbohydrates in Drug Design. pp. 277–308. ISBN 0-8247-9982-8.
  7. ↑ {{U.S. Pharmacopeia Heparin Stage Two Monograph Revisions Open Microphone Web Meeting March 3, 2009 Powerpoint Presentation. Morris, Tina S.; Szajeck, Anita; Wahab, Samir; Ambrose, Michael; Jameison, Fabian A.; <http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/key-issues/2009-03-09-HeparinMeeting.pdf> }}
  8. ↑ USP Safety Data Sheet: Heparin Sodium with Oversulfated Chondroitin Sulfate. http://static.usp.org/pdf/EN/referenceStandards/msds/1304050.pdf Accessed on 11/30/2015.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.